FOR IMMEDIATE RELEASE

Share Purchase Plan Cleansing Notice

Notice under ASIC Class Order [CO 09/425]

Sydney, Australia 10th December 2010 - NuSep (ASX: NSP) wishes to advise the market that on 9 December 2010, NuSep Holdings Limited (NuSep) is proposing to conduct a Share Purchase Plan offer.

NuSep hereby states:

1. Under the Share Purchase Plan offer, NuSep will offer fully paid ordinary shares in the capital of the Company (New Shares) for issue without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) (Act).
2. NuSep is giving this notice under ASIC Class Order [CO 09/425].
3. As at the date of this notice, NuSep has complied with:
    a. the provisions of Chapter 2M of the Act as they apply to the Company; and
    b. section 674 of the Act.
4. As at the date of this notice there is no information
    a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
    b. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
        i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
        ii. the rights and liabilities attaching to the New Shares.

END

For more information please contact:

Contact:
Prakash Patel
Company Secretary
+61 2 8415 7300
prakash.patel@nusep.com

Released through: Fergus Ross, Six Degrees Investor Communication: +61 420 980 448

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from ***Fraction to Function***. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

- **Gels** – NuSep manufactures and sells precast gels including the innovative ηUView Gels, which can be visualised 2 minutes after use.
- **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and is expected to undergoing clinical trials later this year.
- **Proteomics Software** – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
- **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

About SingaPharm

SingaPharm is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. SingaPharm is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). SingaPharm's process is based on the **Pr**eparative **I**solation by **M**embrane **E**lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is 'electronically' driven membrane fractionation.

This process is flexible and modular compared with the large scale inflexible processing facilities of existing fractionators in US and Europe. The process has increased product yield relative to the existing process with increased product safety. The flexible nature of the PrIME technology also provides SingaPharm with access to plasma volumes that previously did not meet the criteria for larger scale processing facilities. Further, SingaPharm's process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

For more information about SingaPharm please visit the company's website www.singapharm.com